Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MT-302 |
| Synonyms | |
| Therapy Description |
MT-302 are lipid nanoparticles containing mRNA encoding a chimeric antigen receptor (CAR) targeting TROP2, which may induce tumor killing (Cancer Res 2023;83(8_Suppl):Abstract nr LB027, Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MT-302 | MT302|MT 302 | MT-302 are lipid nanoparticles containing mRNA encoding a chimeric antigen receptor (CAR) targeting TROP2, which may induce tumor killing (Cancer Res 2023;83(8_Suppl):Abstract nr LB027, Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |